Pluri Inc. Restricted Cash and Cash Equivalents
Pluri Inc. (PLUR) had Restricted Cash and Cash Equivalents of $1.05 million as of 2026-06-30, per its 10-K filed 2026-09-10.
Financial Statements › Balance Sheet › Assets › Restricted Cash and Cash Equivalent
us-gaap:RestrictedCashAndCashEquivalents · last filed 2026-09-10
- 2026-06-30: Restricted Cash and Cash Equivalents $1.05M.
- 2026-03-31: Restricted Cash and Cash Equivalents $1.17M.
- 2025-12-31: Restricted Cash and Cash Equivalents $1.16M.
- 2025-09-30: Restricted Cash and Cash Equivalents $1.34M.
| Period end | Restricted Cash and Cash Equivalents |
|---|---|
| 2026-06-30 | $1.05M 10-K · filed 2026-09-10 |
| 2026-03-31 | $1.17M 10-Q · filed 2026-05-14 |
| 2025-12-31 | $1.16M 10-Q · filed 2026-02-12 |
| 2025-09-30 | $1.34M 10-Q · filed 2025-11-12 |
| 2025-06-30 | $1.30M 10-K · filed 2025-09-17 |
| 2025-03-31 | $1.19M 10-Q · filed 2025-05-13 |
| 2024-12-31 | $1.06M 10-Q · filed 2025-02-11 |
| 2024-09-30 | $1.02M 10-Q · filed 2024-11-12 |
| 2024-06-30 | $888.00K 10-K · filed 2024-09-18 |
| 2024-03-31 | $910.00K 10-Q · filed 2024-05-09 |
| 2023-12-31 | $1.02M 10-Q · filed 2024-02-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B |